Clinical Study
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Table 2
Main patient characteristics.
| Enrolled patients | 43 |
| Median age (range): years | 74 (58–82) | ≥75 years | 21 (48.8%) |
| ECOG performance status | | 0 | 9 | 1-2 | 34 |
| Sites of metastases | | Bone | 26 | Bone + prostate cancer | 4 | Bone + prostate cancer + lymph nodes | 4 | Bone + lung | 3 | Prostate cancer + lymph nodes | 3 | Liver + lymph nodes | 2 | Prostate cancer + lung | 1 |
| Median PSA (range), ng/mL | 78 (47–374) |
| Previous treatment | | Prostatectomy | 31 | Radiotherapy | 9 |
| Hormone therapy | | 1 | 28 | ≥2 | 15 |
| Prior first-line chemotherapy | | w-Epirubicin + w-docetaxel | 21 | 3-w Docetaxel + prednisone | 15 | w-Docetaxel + prednisone | 7 |
| Number of chemotherapy regimens | | 2 | 43 | >2 | 23 |
| Prior third-line chemotherapy | | Docetaxel + prednisone | 23 |
| Best response to prior first-line chemotherapy | | PSA decline ≥50% | 31 | Stable disease | 7 | Progressive disease | 5 | Baseline pain intensity | | 0 | 0 | 1 | 8 | 2 | 22 | 3 | 8 | 4 | 5 | 5 | 0 |
| Median hemoglobin, g/dL | 10.4 | Range | 7.9–13.8 |
|
|